The high expression levels of CD274 and IL8 in basal-like breast cancer were validated by qRT-PCR and western blot, suggesting that clinical CD274- and IL8-targeting therapies may be more suitable for basal-like breast cancer. The gene discussed is CD274; the disease is breast carcinoma.